AVITA Medical Inc

AVITA Medical, Inc. through its subsidiaries, engages in the development and commercialization of technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. Its product RECELL system is a device that enables healthcare professionals to produce a suspension of spray-on skin cells using a small sample of the patient's own skin for the treatment of acute thermal burns. The company is headquartered in Valencia, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AVITA Medical Inc reports robust Q4 earnings and growth outlook

AVITA Medical's strong financial performance in Q4 2022 and full year 2022, coupled with strategic initiatives and growth projections for 2023, position the company for continued success.
While facing challenges in managing expenses and achieving regulatory approvals, AVITA Medical's focus on innovation, market expansion, and operational efficiency presents opportunities for sustained growth.
Investors should monitor the company's progress in securing PMA approvals, expanding market presence, and optimizing operational costs to capitalize on the projected revenue growth and market opportunities.

AVITA Medical reports robust Q1 earnings, eyes FDA approvals

AVITA Medical Inc. delivered strong financial results in Q1 2023, driven by revenue growth and operational improvements.
The company's strategic priorities for 2023 are on track, with pending FDA applications and new product launches in the pipeline.
While facing challenges in operational transitions and market competition, AVITA Medical remains focused on innovation and growth.

AVITA Medical reports strong Q2 performance with FDA milestones

AVITA Medical had a strong quarter with revenue growth and landmark FDA approvals.
The company faces challenges with increased expenses and supply chain issues.
Opportunities lie in market expansion, new FDA approvals, and international growth strategies.
AVITA Medical aims for realistic growth, focusing on hitting guidance targets to build credibility.

AVITA Medical reports robust revenue growth and strategic international expansion

AVITA Medical Inc's Q3 2023 performance reflects strong revenue growth and strategic initiatives to drive international expansion and profitability by 2025.
The company's focus on core business areas, confidence in growth prospects, and commitment to enhancing patient outcomes position it well for future success.
While facing challenges in pricing strategies and global expansion pace, AVITA Medical is poised to capitalize on opportunities in wound care innovation, regulatory approvals, and international market expansion.

AVITA Medical reports strong earnings, eyes global expansion and profitability

AVITA Medical Inc showcased robust financial performance and strategic advancements in Q4 2023 earnings call.
While facing challenges such as net losses and restructuring, the company is well-positioned for growth.
Opportunities lie in product launches, global expansion, and operational efficiency improvements.
Overall, AVITA Medical's performance and outlook signal a promising trajectory for future success.

AVITA Medical Inc reports Q1 revenue miss, eyes profitability by 2025

AVITA Medical Inc faced challenges in Q1 2024 with revenue falling short of expectations, but the company remains focused on strategic initiatives to drive growth and expand its product portfolio. Despite challenges, AVITA is optimistic about its international expansion efforts and aims to achieve profitability by the third quarter of 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. Its product, RECELL system, is a device that enables healthcare professionals to produce a suspension of spray-on skin cells using a small sample of the patient's own skin for the treatment of acute thermal burns. The company was founded in December 1992 and is headquartered in Valencia, CA.

VALENCIA, Calif. and MELBOURNE, Australia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today reported financial results for the third quarter ended September 30, 2022.

AVITA Medical Reports Third Quarter 2022 Financial Results

VALENCIA, Calif. and MELBOURNE, Australia, Nov. 09, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced achievement of co-primary endpoints as a result of updated analysis of data from its clinical trial evaluating the safety and effectiveness of the RECELL® System for soft tissue repair.

AVITA Medical Announces Achievement of Co-Primary Endpoints in Updated Analysis of Pivotal Trial of RECELL® System for Soft Tissue Repair

VALENCIA, Calif. and MELBOURNE, Australia, Nov. 03, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today that the Food and Drug Administration (FDA) granted the RECELL System designations as a Breakthrough Device for its proposed soft tissue repair indication as well as its vitiligo indication.

AVITA Medical Announces FDA Breakthrough Device Designations for the RECELL® System

VALENCIA, Calif. and MELBOURNE, Australia, Oct. 20, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today that it will report its third quarter 2022 financial results after the close of the U.S. financial markets on Thursday, November 10, 2022. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, November 11, 2022, at 8:30 a.m. Australian Eastern Daylight Time) to discuss its financial results and recent highlights.

AVITA Medical to Announce Third Quarter 2022 Financial Results

VALENCIA, Calif. and MELBOURNE, Australia, Sept. 28, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today the appointment of James Corbett as Chief Executive Officer, effective immediately. Mr. Corbett, who has served as a non-executive member of the Board of Directors, will continue as an executive member of the Board of Directors of AVITA Medical, Inc.

AVITA Medical Appoints Industry Leader James Corbett as Chief Executive Officer

Valencia, California and Melbourne, Australia--(Newsfile Corp. - September 19, 2022) - AVITA Medical, Inc. (NASDAQ: RCEL) (ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, invites shareholders and prospective investors to attend its investor webinar and presentation by Dr. Mike Perry, CEO, and Michael Holder, CFO, on September 20, 2022 at 3:30pm (PDT) / September 21, 2022 at 8:30am (AEST).

Investor Webinar Briefing (RCEL, AVH)

VALENCIA, Calif. and MELBOURNE, Australia, Sept. 13, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, invites shareholders and prospective investors to attend its investor webinar and presentation by Dr. Mike Perry, CEO, and Michael Holder, CFO, on September 20, 2022 at 3:30pm (PDT) / September 21, 2022 at 8:30am (AEST).

Investor Webinar Briefing

VALENCIA, Calif. and MELBOURNE, Australia, Sept. 12, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced positive topline results from a pivotal randomized, controlled trial evaluating the safety and effectiveness of the RECELL® System for repigmentation of stable vitiligo lesions.

AVITA Medical Achieves Positive Topline Pivotal Trial Results for Treatment of Stable Vitiligo Using the RECELL® System

Two presentations will highlight data utilizing the RECELL platform for repigmentation Two presentations will highlight data utilizing the RECELL platform for repigmentation

RECELL® System Data to be Presented at the Controversies and Conversations in Laser & Cosmetic Surgery Annual Meeting

AVITA Medical, Inc. (NASDAQ:RCEL ) Q2 2022 Results Conference Call August 11, 2022 5:00 PM ET Company Participants Caroline Corner - Managing Director, Investor Relations Dr. Mike Perry - Chief Executive Officer Michael Holder - Chief Financial Officer Conference Call Participants Josh Jennings - Cowen Ryan Zimmerman - BTIG Operator Hello. Thank you for standing by and welcome to the AVITA Medical Inc. Second Quarter 2022 Earnings Conference Call.

AVITA Medical, Inc. (RCEL) CEO Dr. Mike Perry on Q2 2022 Results - Earnings Call Transcript

VALENCIA, Calif. and MELBOURNE, Australia, Aug. 11, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today reported financial results for its second quarter ended June 30, 2022.

AVITA Medical Reports Second Quarter 2022 Financial Results

VALENCIA, Calif., and MELBOURNE, Australia, July 25, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that it will release its second quarter 2022 financial results on Thursday, August 11, 2022. In conjunction with such release, the Company plans to host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time (Friday, August 12, 2022 at 7:00 a.m. Australian Eastern Standard Time) to discuss its financial results and recent highlights.

AVITA Medical to Announce Second Quarter 2022 Financial Results

The mean of analysts' price targets for Avita Medical Inc. (RCEL) points to a 209.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does Avita Medical Inc. (RCEL) Have the Potential to Rally 210% as Wall Street Analysts Expect?

AVITA Medical, Inc. (NASDAQ:RCEL ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Caroline Corner - Managing Director, Investor Relations Mike Perry - Chief Executive Officer Michael Holder - Chief Financial Officer Conference Call Participants Josh Jennings - Cowen Matthew O'Brien - Piper Sandler Ryan Zimmerman - BTIG Lyanne Harrison - Bank of America John Hester - Bell Potter Operator Good day and thank you for standing by. Welcome to the AVITA Medical Inc. First Quarter 2022 Conference Call.

AVITA Medical, Inc. (RCEL) CEO Mike Perry on Q1 2022 Results - Earnings Call Transcript

VALENCIA, Calif. and MELBOURNE, Australia, May 12, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today reported financial results for its first quarter ended March 31, 2022.

AVITA Medical Reports First Quarter 2022 Financial Results

VALENCIA, Calif. and MELBOURNE, Australia, May 09, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that a discussion on the RECELL System will be held during the Symposium for Cosmetic Advances & Laser Education (SCALE) multidisciplinary dermatology meeting taking place May 11-15 in Nashville, TN. SCALE is the premier multidisciplinary meeting for aesthetic medicine, plastic surgery and medical dermatology.

RECELL® System to be Highlighted at Upcoming Music City SCALE Multidisciplinary Dermatology Meeting

VALENCIA, Calif. and MELBOURNE, Australia, April 28, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that it will release its first quarter 2022 financial results on Thursday, May 12, 2022. In conjunction with such release, the Company plans to host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time (Friday, May 13, 2022 at 6:30 a.m. Australian Eastern Standard Time) to discuss its financial results and recent highlights.

AVITA Medical to Announce First Quarter 2022 Financial Results

VALENCIA, Calif. and MELBOURNE, Australia, March 23, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that an abstract highlighting the clinical trial protocol utilizing the RECELL® Autologous Cell Harvesting Device (RECELL® System) to treat vitiligo will be presented at the Global Vitiligo Foundation Annual Scientific Symposium. The conference is being held in Boston and will highlight research and knowledge of both up and coming vitiligo researchers and those who have and continue to build the foundational knowledge about vitiligo.

RECELL® System Vitiligo Clinical Trial Protocol to be Presented at the Global Vitiligo Foundation Annual Scientific Symposium

Funds will support completion of the ongoing pivotal clinical trial Funds will support completion of the ongoing pivotal clinical trial

AVITA Medical Announces Modification of BARDA Contract to Advance Development of RECELL® System in Soft Tissue Reconstruction

Premier

AVITA Medical Inc (NASDAQ: RCEL) has been awarded a group purchasing agreement with Premier Inc (NASDAQ: PINC) The new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the RECELL System for.

AVITA Medical Inks Supply Pact With Premier For RECELL System

Agreement ensures timely access to the RECELL System for the approximately 4,440 U.S. hospitals and health systems in Premier's network Agreement ensures timely access to the RECELL System for the approximately 4,440 U.S. hospitals and health systems in Premier's network

Avita Medical, Inc. Signs Agreement with Premier, Inc. to Supply the RECELL® System to Hospitals and Health Systems Across the U.S.

AVITA Medical Inc. (RCEL) CEO Mike Perry on Q4 2021 Results - Earnings Call Transcript

VALENCIA, Calif. and MELBOURNE, Australia, Feb. 28, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX:AVH) (the “Company”), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today reported its financial results for the quarter ending December 31, 2021, and its transition period fiscal year ("Transition Period") from July 1, 2021, to December 31, 2021.

AVITA Medical Reports Quarter Ending December 31, 2021, and Transition Period July 1, 2021, to December 31, 2021, Financial Results

VALENCIA, Calif. and MELBOURNE, Australia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that it has received approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) to market the RECELL® System in Japan. COSMOTEC, an M3 Group Company, championed the approval and is AVITA Medical's distribution partner.

The RECELL® System Receives PMDA Approval in Japan and AVITA Medical will Commercialize in Partnership with COSMOTEC, an M3 Group Company

VALENCIA, Calif. and MELBOURNE, Australia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that Dr. Mike Perry, CEO, will present at the Cowen 42nd Annual Health Care Conference on Tuesday, March 8, 2022 at 12:50 p.m. Eastern Standard Time (Wednesday, March 9, 2022 at 4:50 a.m. Australian Eastern Daylight Time).

News for AVITA Medical Inc Stock (RCEL)